Rare Lymphomas

365 Pages·2014·15.305 MB·English

by  Martin Dreyling, Michael E. Williams (eds.)

Hematologic Malignancies
Martin Dreyling
Michael E. Williams Editors
Rare
Lymphomas
Hematologic Malignancies

Martin Dreyling (cid:129) Michael E. Williams
Editors

Rare Lymphomas
Editors
Martin Dreyling, MD Michael E. Williams, MD, ScM
Medizinische Klinik und Poliklinik III Division of Hematology/Oncology
Klinikum Großhadern and Cancer Center
Universität München University of Virginia Health System
München Charlottesville, VA
Germany USA
ISBN 978-3-642-39589-5 ISBN 978-3-642-39590-1 (eBook)
DOI 10.1007/978-3-642-39590-1
Springer Heidelberg New York Dordrecht London
Library of Congress Control Number: 2014930742
© Springer-Verlag Berlin Heidelberg 2014
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed. Exempted from this
legal reservation are brief excerpts in connection with reviews or scholarly analysis or material
supplied specifi cally for the purpose of being entered and executed on a computer system, for
exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is
permitted only under the provisions of the Copyright Law of the Publisher's location, in its
current version, and permission for use must always be obtained from Springer. Permissions for
use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable
to prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specifi c statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility
for any errors or omissions that may be made. The publisher makes no warranty, express or
implied, with respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
To our families, patients and colleagues, with gratitude .

Pref ace
The non-Hodgkin lymphomas represent one of the most prevalent cancer
types worldwide, comprised of a complex and fascinating array of malignan-
cies that are in turn diverse in cell of origin, pathogenesis and clinical presen-
tation. Rapid progress during the past decade in hematopathology and
molecular diagnostics have defi ned more than 50 distinct entities in the cur-
rent World Health Organization classifi cation, leading to continuous refi ne-
ment in treatment approach and, for many lymphomas, improving outcomes
and survival.
G iven these many subtypes, each of them “rare” to a greater or lesser
extent, one may fairly ask why a “rare lymphoma” text devoted to selected
topics is of value. The answers lie in the need for an up-to-date and compre-
hensive treatise for these highly treatable, if not always curable, cancers. The
clinical importance of accurate diagnosis, a thorough understanding of the
cellular and molecular biology of each subtype and optimized management
has never been greater to offer patients the best outcome. There is a parallel
need for basic and translational scientists to understand the spectrum of each
lymphoma and the factors that underlie pathogenesis, prognostic stratifi ca-
tion and therapeutic targets. Indeed, much of current-day cancer biology has
been, and continues to be, informed by insights gained from lymphoma
research. The purpose of this textbook thus is to be an up-to-date and compre-
hensive resource, and to do so at a time of dramatic progress in this rapidly
evolving fi eld.
Rare Lymphomas opens with chapters devoted to key concepts of pathol-
ogy, cytogenetics and molecular genetics, as well as the critical signaling
pathways that are increasingly important to targeted therapeutics. The follow-
ing chapters are devoted to individual T-cell and B-cell lymphomas, organ-
ized to present key elements of diagnosis and staging, prognostic factors,
pathologic and molecular features and current and emerging therapeutics.
Each chapter is coauthored by well-recognized international experts, with
bibliographies that are extensive but selectively organized to identify the
most important advances.
The editors wish to express their appreciation to the authors for their gen-
erosity of time and expertise in preparing each chapter, and especially for
their ongoing contributions to improve the outcomes for patients and families
affected by lymphoma. We also acknowledge the editorial assistance of
vii
viii Preface
Carmen Grimbs and the Springer-Verlag editorial staff including Annette
Hinze, Karthikeyan Gurunathan and Jagannathan Prakash who diligently
communicated with the many authors and assisted in fi nal copy organization.
Finally, we extend sincere appreciation to our readers for their devotion to
improving the understanding, care and cure of non-Hodgkin lymphoma
patients everywhere.
München, Germany Martin Dreyling, MD
Charlottesville, VA, USA Michael E. Williams, MD, ScM
January, 2014
Contents
Part I General
1 Principles of the Pathology and Biology
of Malignant Lymphomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
German Ott, Eric D. Hsi, Jan Delabie, and Scott Rodig
2 Cytogenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Gordana Raca, Jo-Anne van der Krogt, Michelle M. Le Beau,
and Iwona Wlodarska
3 Molecular Genetics of Rare Lymphomas. . . . . . . . . . . . . . . . . . 61
Sören-Sebastian Wenzel and Georg Lenz
4 Signaling Pathways in Rare Lymphomas . . . . . . . . . . . . . . . . . 71
Andrew Lipsky, Patricia Pérez-Galán, Claudio Agostinelli,
Pier Paolo Piccaluga, Stefano A. Pileri, and Adrian Wiestner
Part II Disease-Specifi c: T-NHL
5 Adult T-cell Leukemia-Lymphoma . . . . . . . . . . . . . . . . . . . . . . 99
Kunihiro Tsukasaki and Kensei Tobinai
6 Anaplastic Large Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . 111
Anas Younes, Pier Luigi Zinzani, Scott Rodig, and Jan Delabie
7 Extranodal NK/T-Cell Lymphoma, Nasal Type . . . . . . . . . . . . 121
Won Seog Kim, Seok Jin Kim, and Young Hyeh Ko
8 Cutaneous T-Cell Lymphoma. . . . . . . . . . . . . . . . . . . . . . . . . . . 133
Jasmine Zain, Michael Weichenthal, Scott Rodig,
and Jan Delabie
Part III Disease-Specifi c: B-NHL
9 Adult Burkitt Lymphoma and Leukemia . . . . . . . . . . . . . . . . . 171
Nicola Gökbuget, Paul Barr, Jonathan W. Friedberg,
Eric D. Hsi, and German Ott
10 Primary Mediastinal Large B-Cell Lymphoma . . . . . . . . . . . . 195
Peter Johnson, Jan Delabie, Scott Rodig, and Maurizio Martelli
ix